Back
 

View:
Mini 
BasicThis view is available after user registration.
 
ShortThis view is available when you buy a license.
 
StandardThis view is available when you buy a license.
 
CompleteThis view is available when you buy a license.
 

Brigatinib 180, Non-Small Cell Lung Cancer, First-Line, Cycle 2+

Protocol-ID: 49 V1.0 (Mini), BRGT180, NSCLC, first-line, C2+

Indication(s)

  • Lung Carcinoma, Non-Small Cell (ALK+); ICD-10 C34.-
The publishers and authors assume no liability for the accuracy of the contents. The application is at the own responsibility of the treating physician. ©Onkopti.

Valid since: 21.12.2018